At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

In May 2025, Alnylam Pharmaceuticals announced its plan to present new data from its transthyretin amyloidosis (TTR) franchise at the Heart Failure 2025 Congress, alongside securing broader ...

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) on Saturday released additional data from its Phase 3 HELIOS-B trial, which evaluated its recently approved RNAi therapy Amvuttra (vutrisiran) in patients ...

Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapies with a market capitalization of $32.75 billion, will showcase new data from its ...

Alnylam Pharmaceuticals has shared positive new results from a late-stage trial of its RNAi therapeutic Amvuttra (vutrisiran) in transthyretin amyloid cardiomyopathy (ATTR-CM), an under-diagnosed and ...

According to Mara Molinello, head of rare disease at Alnylam Pharmaceuticals, the drugmaker’s latest patient ambassador is able to tell her story most effectively through art — dance in particular.